Completed PHASE3 INTERVENTIONAL 2-arm NCT00719797

Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (TRIBE)

A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

Sponsor: Gruppo Oncologico del Nord-Ovest

Conditions Colorectal Cancer

Interventions bevacizumab fluorouracil irinotecan hydrochloride leucovorin calcium oxaliplatin

Updated 6 times since 2017 Last updated: Mar 10, 2015 Started: Jul 31, 2008 Primary completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Colorectal Cancer, this trial is completed. The trial is conducted by Gruppo Oncologico del Nord-Ovest and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gruppo Oncologico del Nord-Ovest

Data source: Gruppo Oncologico del Nord-Ovest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Ancona, Italy , Arezzo, Italy , Aviano, Italy , Brescia, Italy , Brindisi, Italy , Caltanissetta, Italy , Carrara, Italy , Cecina, Italy , Cremona, Italy and 27 more locations